Shares

Welcome Transcranial Electric Stimulation to Our Plan

Non-invasive techniques are changing the landscape of neuroscience. Among them include transcranial electric stimulation (tES). PointKetamine would like to welcome this therapy into our treatment plan. The device has been FDA cleared since 1993 for the treatment of depression, anxiety, insomnia and chronic pain. The compact instrument consists of a pair of electrodes that receives current from a battery. The device delivers low current (1-5 mA) directly to the head for several minutes.

The electrical current stimulates neuronal activity. Studies demonstrate that transcranial electrical stimulation (tES) can modulate a wide-range of behavioral processes (Coffman et al., 2014; Harty et al., 2014; Sarkar et al; Pasqualotto, 2016).

Neurological disorders, such as chronic pain, Parkinson’s disease, motor impairment and epilepsy are responding to tES treatments in profound ways (Miniussi and Vallar, 2011; Miniussi et al., 2008; Celnik et al., 2009; Fregni and Pascual-Leone, 2007; Harris-Love and Cohen, 2006).

The TES technique is proving its value in treatment for mental health and pain. The promising results, while being safe and affordable has lead to the growing enthusiasm around the innovation. Researchers are seeing cognitive improvements last beyond the stimulation period. PointKetamine looks forward to integrating this technique to our care plans. We aspire to create opportunities for patients.